399
Participants
Start Date
February 28, 2009
Primary Completion Date
March 31, 2010
Study Completion Date
December 31, 2011
Icotinib
125 mg three times daily (375 mg per day) by mouth
Gefitinib
250 mg every 24 hours by mouth
Beijing Chao-Yang Hospital, Beijing
Cancer Hospital, Chinese Academy of Medical Science, Beijing
Peking Union Medical College Hospital, Beijing
Bejing Cancer Hospital, Beijing
307 Hospital of PLA, Beijing
Peking University Third Hospital, Beijing
Chinese PLA General Hospital, Beijing
Beijing Chest Hospital, Beijing
Jilin Cancer Hospital, Changchun
Ruijin Hospital，Shanghai Jiao-Tong University, Shanghai
Zhongshan Hospital，Fudan University, Shanghai
Changhai Hospital， Second Military Medical University, Shanghai
Shanghai Pulmonary Hospital, Shanghai
81 Hospital of PLA, Nanjing
Nanjing General Hospital of Nanjing Command，PLA, Nanjing
Jiangsu Cancer Hospital, Nanjing
The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou
Zhejiang Cancer Hospital, Hangzhou
Third Affiliated Hospital, Third Military Medical University, Chongqing
the Second Xiangya Hospital，Central South University, Changsha
Hunan Cancer Hospital, Changsha
Guanghzou General Hospital of PLA, Guangzhou
Sun yat-sen Univerisity Cancer Center, Guanzhou
Guangdong General Hospital, Guangzhou
Nanfang Hospital， Southern Medical University, Guangzhou
Tangdu Hospital, Fourth Military Medical University, Xi’an
Xijing Hospital, Fourth Military Medical University, Xi’an
Lead Sponsor
Betta Pharmaceuticals Co., Ltd.
INDUSTRY